BRAF and metastatic melanoma: In a clinical trial on advanced metastatic melanoma, pre-treatment with BRAF and MEK inhibitors was used to decrease glycolytic activity in melanomas with BRAF mutations, leading to normalization of LDH levels in 74% of patients over eight weeks85.